Cardiovascular Signals Tirzepatide's cardiovascular outcome trial, SURPASS-CVOT, is ongoing
B-12 support may be discussed when symptoms, history, or nutrition patterns make it relevant Phentermine requires provider judgment and is not appropriate for every patient Nutrition and follow-up planning are part of the program, not an afterthought Telehealth may be appropriate for some follow-ups after the initial medical review How to know if you are ready to start A strong medical weight-loss visit should leave patients with a plan they understand
Retatrutide: Surgery-Level Results from a Triple Agonist The most striking data to emerge from the GLP-1 drug pipeline in 2026 comes from retatrutide, Eli Lillys investigational first-in-class triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously
In our study, we observed a modest improvement or slight reduction in cardiac hypertrophy in MC4R KO mice treated with GLP-1 analogs, which further supports the notion that these drugs have potential cardiovascular benefits
